NCT03930498进行中（未招募）2 期
PD-1 Antibody Combined With Chemotherapy in High-risk Recurrent Nasopharyngeal Carcinoma: a Prospective, Open, Single-arm Phase II Clinical Trial
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2020年3月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 68
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
This is a a prospective, single-arm phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemotherapy in high-risk recurrent nasopharyngeal carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed as local recurrence ± regional recurrence after ≥1 year of radical treatment;
- •Not suitable for surgery;
- •Newly histologic diagnosis of NPC (WHO II/III);
- •Clinical stage rII-IVa (AJCC/UICC 8th);
- •ECOG 0-1 point;
- •PRANCIS score > 252 points;
- •No treatment to rNPC, such as radiotherapy, chemotherapy, immunotherapy or biotherapy;
- •No contraindications to immunotherapy or chemoradiotherapy;
- •Adequate marrow function: WBC count ≥ 3×10E9/L, NE count ≥ 1.5×10E9/L, HGB ≥ 90g/L, PLT count ≥ 100×10E9/L;
- •Adequate liver function: ALT/AST ≤ 2.5×ULN, TBIL ≤ 2.0×ULN;
- •Adequate renal function: BUN/CRE ≤ 1.5×ULN or endogenous creatinine clearance ≥ 60ml/min (Cockcroft-Gault formula);
- •Take effective contraceptions during and two months after treatment;
- •Patients must be informed of the investigational nature of this study and give written informed consent.
排除标准
- •Have recurrence with local necrosis;
- •Have ≥G3 late toxicities, except for skin, subcutaneous tissue or mucosa;
- •Unexplained fever > 38.5 ℃, except for tumor fever;
- •Treated with ≥ 5 days antibiotics one month before enrollment;
- •Have active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy);
- •Have a known history of human immunodeficiency virus (HIV), active Hepatitis B (HBV-DNA ≥10E3copiers/ml) or hepatitis C virus (HCV) antibody positive;
- •Have previously treated with PD-1 antibody or other immunotherapy for PD-1/PD-L1 pathway;
- •Have New York Heart Association (NYHA) class 3 or 4, unstable angina, myocardial -infarction within 1 year, or clinically meaningful arrhythmia that requires treatment;
- •Have known allergy to large molecule protein products or any compound of study therapy;
- •Pregnant or breastfeeding;
- •Prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical cancer, and papillary thyroid carcinoma;
- •Have received a live vaccine within 30 days of planned start of study therapy Has psychiatric drug or substance abuse disorders that would interfere with cooperation with the requirements of the trial;
- •Any other condition, including mental illness or domestic/social factors, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results.
研究组 & 干预措施
PD-1 antibody plus chemoradiotherapy
Experimental
干预措施: PD-1 blocking antibody (Drug)
PD-1 antibody plus chemoradiotherapy
Experimental
干预措施: Chemotherapy (Drug)
PD-1 antibody plus chemoradiotherapy
Experimental
干预措施: IMRT (Radiation)
结局指标
主要结局
Overall survival
时间窗: 2 years
From date of recruitment to death
次要结局
- Objective response rate(After 3 cycles of GP chemothrapy plus PD-1 antibody (each cycle is 21 days))
- Progression free survival(2 years)
- Disease control rate(After 3 cycles of GP chemothrapy plus PD-1 antibody (each cycle is 21 days))
- Adverse effects(through study completion, an average of 3 months)
- Quality of life: EuroQoL 5 dimension(through whole study, an average of 2 years)
研究者
Zhao Chong
Prof.
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLsPrimary Mediastinal Large B-cell LymphomaNCT03346642Chinese PLA General Hospital30
已完成
2 期
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon MutationsLung CancerNCT04790409Zhejiang Cancer Hospital21
招募中
不适用
Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON TrialNon-small Cell Lung CancerNCT04322591Hunan Province Tumor Hospital70
招募中
不适用
Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLCNon Small Cell Lung CancerNCT04324125Hunan Province Tumor Hospital70
Unknown
2 期
PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction AdenocarcinomaGastric or Gastroesophageal Junction AdenocarcinomaAFPNCT04098796China Medical University, China30